74
Participants
Start Date
July 27, 2018
Primary Completion Date
September 24, 2021
Study Completion Date
December 1, 2022
lisocabtagene maraleucel
lisocabtagene maraleucel will be administered as a single dose intravenous (IV) injection
New York Oncology Hematology - Albany Cancer Center, Albany
New York Oncology Hematology P.C., Albany
Local Institution - 0090, Rochester
University of Rochester Cancer Center, Rochester
University of Rochester Medical Center, Rochester
Local Institution - 0029, Pittsburgh
University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh
Johns Hopkins Oncology Center Bunting Blaustein Building, Baltimore
Local Institution - 0009, Baltimore
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Levine Cancer Institute, Charlotte
Local Institution - 0021, Charlotte
Greenville Health System - Cancer Institute - Faris Road, Greenville
Greenville Health System, Greenville
Local Institution - 0037, Greenville
Local Institution - 0019, Atlanta
The Blood and Marrow Transplant Group of Georgia, Atlanta
UNC School of Medicine, Atlanta
Local Institution - 0064, Louisville
Norton Cancer Institute - Brownsboro, Louisville
UNC School of Medicine, Louisville
Local Institution - 0046, Lexington
University of Kentucky/Markey Cancer Center, Lexington
University of Kentucky, Lexington
Local Institution - 0039, Cincinnati
Oncology Hematology Care, Inc., Cincinnati
Oncology Hematology Care, Cincinnati
Local Institution - 0055, Milwaukee
Medical College of Wisconsin, Froedtert Hospital, Milwaukee
UNC School of Medicine, Milwaukee
Local Institution - 0003, Chicago
Northwestern University Feinberg School of Medicine, Chicago
Northwestern University, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
UNC School of Medicine, Dallas
Intermountain Healthcare - LDS Hospital Blood and Marrow Transplant, Salt Lake City
Intermountain Healthcare - LDS Hospital, Salt Lake City
Local Institution - 0074, Salt Lake City
Banner MD Anderson Cancer Center, Gilbert
Local Institution - 0043, Gilbert
UNC School of Medicine, Los Angeles
University of California Los Angeles, Los Angeles
Scripps Clinic, La Jolla
Stanford Cancer Genetics Clinic, Stanford
Local Institution - 0092, Stanford
Stanford Cancer Center, Stanford
Sutter Hematology and Oncology, Sacramento
Sutter Medical Center, Sacramento
Local Institution - 0051, Portland
Providence Cancer Center/Earle A. Chiles Res. Inst., Portland
Providence Portland Medical Center, Portland
Northwest Medical Specialties, Tacoma
UNC School of Medicine, Tacoma
Local Institution - 0016, Chicago
University of Chicago, Chicago
Local Institution - 0052, East Brunswick
Regional Cancer Care Associates, East Brunswick
UNC School of Medicine, East Brunswick
Local Institution - 0083, Dallas
Juno Therapeutics, a Subsidiary of Celgene
INDUSTRY